Tectonic Therapeutic (TECX) Q4 2025 earnings summary

Executive summary

• Achieved positive topline results from TX45 Phase 1b trial in Group 2 PH-HFrEF, showing improved left heart function and pulmonary hemodynamics.

• Advanced TX2100 into Phase 1a clinical trial for HHT and TX45 into Phase 2 for PH-ILD in early 2026.

• Cash and cash equivalents of $253.8 million as of December 31, 2025, expected to fund operations into Q4 2028.

• Appointed François Nader, M.D., MBA, as independent director and Chair of the Board effective April 2026.

Financial highlights

• Cash and cash equivalents were $253.8 million at year-end 2025, up from $141.2 million at year-end 2024.

• Research and development expenses rose to $16.3 million in Q4 2025 from $9.2 million in Q4 2024, driven by CRO and stock-based compensation costs.

• General and administrative expenses were $5.2 million in Q4 2025, up from $4.8 million in Q4 2024.

• Net loss for Q4 2025 was $19.2 million, compared to $12.4 million in Q4 2024; full-year net loss was $74.2 million versus $58.0 million in 2024.

• Total stockholders' equity increased to $251.3 million at year-end 2025 from $140.8 million at year-end 2024.

Outlook and guidance

• Cash runway expected to last into Q4 2028, supporting ongoing and planned clinical trials.

• Topline results for TX45 APEX Phase 2 trial in PH-HFpEF expected in 2026.

• TX2100 Phase 1a topline results anticipated in Q4 2026, with Phase 2 proof-of-concept trial in HHT planned for early 2027.